NATR stock forecast, quote, news & analysis

Key Takeaways

• Nature's Sunshine Products (NATR) has drifted roughly 2.5% lower over the trailing 30 days, consolidating near the low end of its 52-week range of $12.00 to $28.14.
• The stock has declined about 39% over the trailing three months, largely reflecting a post-earnings selloff after second-quarter results and lowered full-year guidance.
• Wall Street maintains a "Strong Buy" consensus with an average price target of $30.50, well above the current share price.
• China sales weakness and foreign-exchange headwinds remain the primary near-term pressures, while digital, subscription, and geographic expansion anchor the growth story.
• The company operates a debt-free balance sheet with roughly $100 million in cash, supporting its $1 billion sales and 15% EBITDA margin ambitions.

Current Market Snapshot

Nature's Sunshine Products (NATR) trades near $12.70, giving the company a market capitalization of approximately $221 million. The stock sits close to its 52-week low after a steep pullback from levels above $20 seen earlier in 2026. Over the trailing 30 days, shares have moved modestly lower — roughly 2.5% — as trading volume normalized and the stock entered a period of consolidation following a sharp post-earnings decline in early August.

With a trailing price-to-earnings ratio near 12 and a beta around 0.81, NATR screens as a value-oriented, lower-volatility name within the consumer staples and wellness space. The company pays no dividend, positioning the equity story around capital appreciation and its long-term growth plan rather than income.

Nature's Sunshine Products (NATR) Business Overview and Competitive Position

Founded in 1972 and headquartered in Lehi, Utah, Nature's Sunshine Products is a natural health and wellness company that manufactures and markets nutritional supplements and personal care products in more than 40 countries. The company distributes a portfolio of over 800 products across general health, immune, cardiovascular, digestive, personal care, and weight management categories under two primary brands: Nature's Sunshine and Synergy Worldwide.

Its distribution model relies on independent consultants and direct selling, complemented by a fast-growing direct-to-consumer digital channel. Nature's Sunshine manufactures more than 90% of its products in-house through its Utah facilities, a vertically integrated approach that supports quality control and gross margins of roughly 73%. The company reported approximately $480 million in revenue in 2025 and generated a 10% EBITDA margin, while maintaining a debt-free balance sheet and nearly $100 million in cash.

Management has laid out a vision to double sales to $1 billion and expand EBITDA margins to 15% through geographic penetration, channel diversification, marketing initiatives, and strategic acquisitions. That growth agenda — combined with its expanding digital business, which is on track to reach about $50 million in annual revenue — keeps the stock on investors' watchlists despite recent share-price weakness.

Recent Developments Driving NATR

The dominant event shaping NATR's recent trajectory remains its second-quarter 2026 report, released in early August. Net sales reached a record $117 million, up 2% year over year, with gross margin of 73.7%. However, results fell short of expectations as China sales declined 20%, and management lowered full-year 2026 guidance, citing foreign-exchange pressures and China headwinds. The shares fell sharply in the session following the report, and that decline set the tone for the subsequent months of consolidation.

In the most recent 30 days, trading has been comparatively quiet, with the stock ranging between roughly $12.40 and $13.50 on lighter-than-average volume as investors awaited fresh catalysts. Leadership changes have continued to unfold, including the arrival of Ruth Perkins as executive vice president and chief financial officer effective September 1, bringing finance experience from Ford, Estée Lauder, and PepsiCo. On the analyst front, DA Davidson lowered its price target to $25 from $33 while maintaining a Buy rating. Meanwhile, the company has reiterated its $1 billion sales target and highlighted progress in digital growth, subscription revenue, and its entry into Germany.

Trending AI Robots

Investors tracking names like Nature's Sunshine Products can also monitor quantitative and algorithmic strategies through Tickeron's Trending AI Robots page. Tickeron offers hundreds of AI-powered trading bots that trade thousands of tickers, but only the top-performing and most relevant bots are featured in this curated section. These bots vary considerably in strategy, timeframe, and performance metrics, allowing users to review a range of approaches rather than a single system. The page is designed to help traders discover currently popular and effective automated strategies in one place, offering a convenient starting point for those interested in data-driven trading tools.

2026 Outlook and What Investors Should Watch

Looking ahead, the company's third-quarter earnings, expected in early November 2026, represent the next major catalyst. Investors will focus on whether China sales stabilize, how foreign-exchange movements affect results, and whether the digital and subscription businesses continue their double-digit growth. Management has also signaled plans to enter an additional Asian market pending regulatory approvals and to test larger U.S. retail channels.

Product innovation remains a key theme, with efforts centered on digestive health, women's health, skincare in Asian markets, and supplements designed to support consumers using GLP-1 therapies. The company's nearly $100 million cash position and absence of debt provide capacity for accretive bolt-on acquisitions and opportunistic share repurchases. The wide gap between the current share price and the $30.50 average analyst target underscores the market's caution around execution risks in China and direct-selling fundamentals, even as the balance sheet and long-term growth plan remain intact.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations